- 1 Clinical Testing of Pediatric Mpox Specimens: Unique Features and Challenges in a Low Prevalence
- 2 Population
- 3
- 4 Angela Ma^{1,2} and Benjamin T. Bradley^{1,2 #}
- 5
- 6 ¹ Department of Pathology, University of Utah, Salt Lake City, UT
- 7 ² ARUP Laboratories, Salt Lake City, UT
- 8
- 9 [#]Corresponding author
- 10 Benjamin T. Bradley, <u>ben.bradley@hsc.utah.edu</u>
- 11 500 Chipeta Way, Salt Lake City, UT
- 12
- 13 Keywords: monkeypox virus, mpox, pediatric, pcr, false positive
- 14

15 Abstract

- 16 BACKGROUND: Pediatric mpox cases comprise less than 0.3% of the total cases reported in the United
- 17 States during the global 2022 outbreak. As a result, relatively little is known about the epidemiology or
- 18 performance characteristics of clinical testing in this group.
- 19 METHODS: We retrospectively extracted and analyzed results for pediatric mpox specimens tested at a
- 20 national reference laboratory from July to December 2022.
- 21 RESULTS: During our study period 13.4% (2,063/15,385) of specimens were from individuals <18 years of
- age. The positivity rate of pediatric specimens was significantly lower than in adults (1.3% vs 22.3%). The
- 23 pediatric cohort also consisted of a higher percentage of females (42.7% vs 31.0%) and lower
- 24 percentage of specimens from genital sources (9.0% vs 19.7%) as compared to adults. In children,
- 25 specimens were most frequently collected from 1-year-olds (10.1%) and least frequently from 11-year-
- olds (3.5%). Positivity rates were disproportionately elevated in the less than 1-year and 17-year-old age
- 27 groups (7.8% and 6.4%, respectively). Ct values of positive cases were not statistically different between
- pediatric and adult cohorts (25.2 vs 22.2, p>0.05). When all pediatric cases with an initial positive mpox
- result were examined, 5/26 were classified as inconclusive and 2/26 were determined to be false
- 30 positives. Based on these results, the positive predictive value of monkeypox virus detection was 90.5%
- 31 (95% CI: 70.4-97.4%) in children.
- 32 CONCLUSION: These results highlight important differences between pediatric and adult mpox
- 33 populations and reinforce the need for clinical correlation when reporting positive results from a low
- 34 prevalence population.
- 35

36 Introduction

37 Monkeypox virus (MPXV) is the etiologic agent of mpox (1). Historically, mpox has been 38 observed in endemic regions of Africa with rare, sporadic outbreaks in non-endemic regions (2, 3). 39 However, in the spring of 2022, several non-endemic countries began reporting sustained human-to-40 human transmission of MPXV (4). The resulting global outbreak has led to mpox being declared a Public 41 Health Emergency of International Concern by the World Health Organization (5). Epidemiological 42 reports of the 2022 mpox outbreak have differed from prior accounts of mpox in several important 43 ways. Historically, children have been most commonly affected and present with lesions on the 44 extremities (6). The current outbreak has predominately affected populations of men who have sex with 45 men and has been associated with transmission during intimate contact (7). The Centers for Disease Control and Prevention estimate less than 0.3% of mpox cases occur in individuals less than 18 years of 46 47 age (8). 48 Traditionally, children have comprised the largest group affected by mpox with the median age 49 of infection being 4 and 5 years old for cases reported in the 1970s and 1980s; however, the median age 50 has increased in recent decades (6). Childhood mpox has also been associated with a high mortality rate, 51 up to 10% during the 1980s (9). However, in a recent meta-analysis of Clade II MPXV cases prior to 2022, 52 22 pediatric cases were identified with only one documented death (10). During the current outbreak, 53 reports from Spain and the United States found severe complications were rare in pediatric patients and

no intensive care unit admissions or deaths were documented (8, 11). For cases of mpox in children less
than 18 years old, two main transmission routes have been identified, each specific to certain age
groups. For individuals less than 13 years of age, transmission from household contacts the most
common source of infection. Whereas, in adolescents, sexual activity was the source for 97% of


58 infections with a known transmission route (8).

59	Diagnosing infectious diseases in a low-risk population presents a challenge to clinical
60	microbiology laboratories. The most concerning dilemma is the risk for reporting false positive results
61	due to poor positive predictive value in a low prevalence setting. As demonstrated during the SARS-CoV-
62	2 pandemic, the clinical value of a positive result was compromised when surveillance testing was
63	performed in a low-risk population (12). Mpox testing in pediatric populations is also complicated by the
64	presence of viral exanthems which may present with similar clinical features including varicella,
65	molluscum contagiosum, and hand foot and mouth disease (13). False positive results may lead to
66	inappropriate treatment, unnecessary prophylactic vaccination of close contacts, and unintended social
67	stigma (14). To better understand how mpox testing differs from adult populations and examine
68	relevant differences in positivity rates, we performed a retrospective review of all pediatric mpox testing
69	performed at a national reference laboratory between July 25 th and December 14 th , 2022.
70	
71	Methods
71 72	Methods Ethics Statement
72	Ethics Statement
72 73	<i>Ethics Statement</i> An IRB exemption was granted by the University of Utah IRB under ID#: 00158025.
72 73 74	Ethics Statement An IRB exemption was granted by the University of Utah IRB under ID#: 00158025. MPXV NAAT Testing
72 73 74 75	Ethics Statement An IRB exemption was granted by the University of Utah IRB under ID#: 00158025. MPXV NAAT Testing Detection of MPXV DNA was performed as previously described (15). In brief, specimens were
72 73 74 75 76	Ethics Statement An IRB exemption was granted by the University of Utah IRB under ID#: 00158025. MPXV NAAT Testing Detection of MPXV DNA was performed as previously described (15). In brief, specimens were either extracted on the Chemagic MSMI instrument (PerkinElmer) followed by amplification on the
72 73 74 75 76 77	Ethics Statement An IRB exemption was granted by the University of Utah IRB under ID#: 00158025. MPXV NAAT Testing Detection of MPXV DNA was performed as previously described (15). In brief, specimens were either extracted on the Chemagic MSMI instrument (PerkinElmer) followed by amplification on the QuantStudio 12K Flex (ThermoFisher) or extraction and amplification was performed on the cobas 6800
72 73 74 75 76 77 78	Ethics Statement An IRB exemption was granted by the University of Utah IRB under ID#: 00158025. MPXV NAAT Testing Detection of MPXV DNA was performed as previously described (15). In brief, specimens were either extracted on the Chemagic MSMI instrument (PerkinElmer) followed by amplification on the QuantStudio 12K Flex (ThermoFisher) or extraction and amplification was performed on the cobas 6800 platform (Roche Diagnostics). Both assays used lab-developed primers and probes which targeted a
72 73 74 75 76 77 78 79	Ethics Statement An IRB exemption was granted by the University of Utah IRB under ID#: 00158025. MPXV NAAT Testing Detection of MPXV DNA was performed as previously described (15). In brief, specimens were either extracted on the Chemagic MSMI instrument (PerkinElmer) followed by amplification on the QuantStudio 12K Flex (ThermoFisher) or extraction and amplification was performed on the cobas 6800 platform (Roche Diagnostics). Both assays used lab-developed primers and probes which targeted a conserved region of the viral polymerase gene common to the Orthopoxvirus family (16).

"anal", "buttock", "gluteal", "groin", "inguinal", "labia", "penis", "perineum", "pubic", "rectal", 83 84 "scrotum", "vagina", "vulva" or variations of such words. Deidentified data were analyzed in Prism 85 Graphpad v. 9.4.1. Statistical tests included Chi-squared, Mann-Whitney, Fisher's exact, and Welch's ttest. The cutoff for statistical significance for all tests was established as 0.05. 86 87 Specimens were categorized as "detected", "inconclusive", or "not detected". Specimens with 88 no repeat testing were categorized as follows: detected if Ct<34, inconclusive if Ct=34-50, and not 89 detected if CT >50. Specimens with repeat testing were categorized as follows: detected if Ct <50 for 90 both replicates, inconclusive if one replicate with Ct<50 and the other Ct>50, and not detected if both 91 replicates with Ct>50. 92 Patient cases were classified as "positive", "inconclusive", or "false positive". A positive case was 93 classified as any individual with at least one detected specimen. An inconclusive case was classified as 94 any individual with at least one inconclusive specimen and no detected specimens. Cases were classified 95 as false positive only in situations where the ordering provider provided a clinical history not consistent 96 with mpox and repeat testing of the specimen was not detected. 97 Results 98 Pediatric mpox specimens have different demographics and positivity rates from adult specimens 99 100 During the study period, pediatric specimens comprised 13.4% (2,063/15,385) of the total mpox 101 testing volume (Fig 1A). The proportion of pediatric to adult individuals within the cohort was similar at 102 13.6% (1,480/10,862). The pediatric cohort was comprised of 56.8% male, 42.7% female, and 0.5% of 103 individuals with unknown sex, while the adult cohort contained 66.8% male, 31.0% female, and 2.2% of 104 individuals with unknown sex (Fig 1B). The sex distribution was significantly different between the two 105 age groups (p<0.001, chi-squared test, individuals with unknown sex excluded). 9.0% of specimens were 106 collected from genital sources in the pediatric cohort while 19.6% of adult specimens were collected

from genital sources (p<0.001, chi-squared) (Fig 1C). The positivity rates of the pediatric and adult cohorts were 1.3% and 22.3%, respectively. When stratified by sex, the positivity rate of the female pediatric cohort was 1.1% and the male pediatric cohort was 1.4% (p=0.565, Fisher's exact test). In the adult cohort, the positivity rate between females and males was 3.2% and 31.1% (p<0.0001, chisquared) (Fig 1D). The median Ct value of specimens from pediatric individuals positive for mpox was 25.2 while the median Ct value for adult specimens was 22.2. The difference was not statistically significant (p=0.146, Mann-Whitney test) (Fig 1E).







117 Percent of total specimen volume. (B) Percent of female, male, and unknown sex. (C) Percent of


118 specimens obtained from genital or non-genital sources. (D) Positivity rate of pediatric and adult

119 specimens stratified by sex. (E) Comparison of Ct values between pediatric and adult specimens positive

120 for mpox

121 Mpox positivity rates are highest at the extremes of the pediatric age group

- 122 The median age and standard deviation of the pediatric cohort was 6 ± 5.4 years. 1-year-olds were the most frequently tested group (10.1%), followed by 2-year-olds (9.2%), 3-year-olds (8.2%), and 123 124 17-year-olds (7.3%). 11-year-olds were the least frequently tested group (3.5%) (Fig 2A). Age distribution 125 of mpox cases demonstrated bimodal peaks with the highest number of positive cases in 17-year-olds 126 (36.8%) followed by <1-year-olds (26.3%). Single positive cases were identified in 1, 2, 6, 8, 9, 14, and 16 127 year-olds (Fig 2B). Mpox positivity rates by age were calculated as follows: <1 year of age – 7.8%, 1-year-128 olds – 0.9%, 2-year-olds – 0.7%, 6-year-olds – 1.1%, 8-year-olds - 1.4%, 9-year-olds – 1.9%, 14-year-olds 129 - 1.6%, 16-year-olds - 1.3%, and 17-year-olds - 6.4%. The mean age for pediatric mpox diagnosis was 130 significantly earlier for females (4.5 years) than males (11.6 years) (p=0.039, Welch's t test). Ct values for 131 positive cases ranged from 18.2 to 37.1 based on the earliest Ct available per patient. Ct values were not
- 132 statistically different between age groups or sex (Fig 2C).



133

Figure 2. Mpox Results by Age and Sex in the Pediatric Cohort. (A) Age distribution of total pediatric
 mpox testing. (B) Age distribution of positive mpox cases. (C) Earliest Ct value for individual positive
 cases of mpox.

137

138	A significant proportion of mpox detected in children result in inconclusive or false positives results
139	Of the 26 individuals with MPXV amplified at least once from a specimen, 19 (73%) were
140	determined to be positive for mpox, 5 (19%) inconclusive for mpox, and 2 (8%) false positive for mpox
141	(Table 1). Excluding the inconclusive specimens, assay sensitivity and specificity was 100% (95% CI: 82.4-
142	100%) and 99.9 (95% CI: 99.5-100.0), respectively. The positive predictive value was 90.5% (95% CI: 70.4-
143	97.4%) and the negative predictive value was 100% (no known false negative cases).
144	Based on additional clinical information obtained following discussion with the ordering
145	provider, two cases (Pt 8 and Pt 15) were determined to represent false positive results. Both of these
146	cases demonstrated late Ct values of 35.2 and 39.1 that did not repeat following re-extraction and
147	amplification. Additionally, one case was adjudicated as positive despite one of two specimens not
148	repeating. This patient (Pt 23) initially had late Cts detected in both specimens (37.1 and 38.5). The 37.1
149	specimen repeated at 37.6, however, the 38.5 specimen did not repeat.
150	When positive samples were repeated (n=16), the median Ct value shifted by 0.1 cycles (range: -
151	1.7 to 0.6 cycles). For samples that failed to repeat, the earliest Ct value that did not yield a repeatable
152	result was 33.3 (Pt. 17). Repeat testing of all positive pediatric results was instituted during the study
153	period on September 17 th , 2022. During that time 11/12 samples in which MPXV was initially detected
154	repeated as positive. The specimen that did not repeat was from the previously described patient (Pt
155	23).

Patient	Sex	Specimen	Specimen source	Initial Ct	Repeat Ct	Specimen result	Patient result
1	F	1	Lesion	50	-	Not detected	Positive
		2	Lesion	50	-	Not detected	
		3	Lesion	21.1	-	Detected	
2	Μ	1	Lesion	21.8	-	Detected	Positive

3	Μ	1	Buttock	35.6	-	Inconclusive	Inconclusive
4	F	1	Abdomen	26.2	-	Detected	Positive
		2	Right hand	28.8	-	Detected	
5	F	1	Finger	20.3	-	Detected	Positive
6	М	1	Anal	31.6	-	Detected	Positive
		2	Arm	24.2	-	Detected	
7	F	1	Face, arm, abdomen	34.3	-	Detected	Inconclusive
		2	Face, arm, abdomen	50	-	Not detected	
8	Μ	1	Lesion	35.2	50	Inconclusive	False positive
9	М	1	Left hand	17.2	-	Detected	Positive
10	М	1	Lesion	23.3	-	Detected	Positive
11	Μ	1	Lesion	29.1	-	Detected	Positive
12	М	1	Right leg	37.9	-	Detected	Positive
		2	Left hand	19.4	-	Detected	
13	M M	1 2	Left arm Right leg	50 35.4	- 50	Not detected Inconclusive	Inconclusive
14	М	1	Lesion	35.9	-	Inconclusive	Inconclusive
15	F	1	Neck	50	-	Not detected	False positive
		2	Left leg	39.1	50	Inconclusive	
16	Μ	1	Lesion	16.6	-	Detected	Positive
17	Μ	1 2	Not Provided Not Provided	33.3 50	50 -	Inconclusive Not detected	Inconclusive
18	М	1	Lesion	16.5	16.4	Detected	Positive
19	М	1	Left hand	19	-	Detected	Positive
20	М	1	Neck	31.4	32	Detected	Positive
21	F	1	Right hand	28.2	27.3	Detected	Positive
		2	Right foot	37.3	35.6	Detected	
		3	Left hand	35.4	35	Detected	
22	Μ	1	Skin	31.7	30.2	Detected	Positive
23	F	1	Neck	37.1	37.6	Detected	Positive
		2	Abdomen	38.5	50	Inconclusive	
24	Μ	1	Lesion	18.6	18.5	Detected	Positive
					-		

25	М	1	Not Provided	28.7	28.6	Detected	Positive
		2	Upper/lower extremity	18.2	18.3	Detected	
26	F	1	Lesion	18.2	18.1	Detected	Positive

157

158 Discussion

Recently, more clinical data is available describing the manifestations of mpox in the pediatric population (8, 11, 17–19). However, this information is mostly outside the context of laboratory testing. In this study we examined the demographics and results of pediatric mpox testing at a large reference laboratory. The results of our study reinforce clinical trends that have been identified and add further clarity on higher risk groups within the pediatric population.

164 The relative percent of pediatric specimens tested in our laboratory decreased from 14.1% 165 when examined in September 2022 to 13.4% by December 2022 (15). Epidemiologic studies of mpox 166 have found a higher relative percentage of female cases among children (20%-36%) than adults and 167 noted an absence of genital lesions in those less than 13-years old (8, 11). This is reflected in the 168 ordering practices for pediatric mpox specimens in our study. We found a higher number of female 169 individuals (42.7% vs 31.0%) and non-genital specimens (91% vs 80.4%) in children versus adults. 170 When examining the distribution of age and gender for pediatric mpox specimens, several 171 trends were observed. First in terms of overall testing volume, 1- to 3-year-olds were the most 172 frequently tested groups with 11-year-olds the least frequently tested. It is interesting that those less 173 than 1 year old were not tested at a higher volume, given over 25% of cases occurred in this age group. 174 This may suggest other types of close contact outside of interactions with caregivers led to preferential 175 testing in 1- to 3-year-olds. Potential exposures may include attendance of community events which was 176 identified as a risk factor for childhood HSV-1 acquisition (20). Second, positivity rates were strongly 177 polarized to the less than 1-year and 17-year-old age groups. The less than 1 age group was comprised 178 of female and male cases while the 17-year-old group was exclusively male. These findings reflect the

179 different modes of transmission between age groups, with infants more likely infected by close skin-to-180 skin contact from caregivers and adolescents infected through sexual contact (8). Ct values between the 181 less than 1- and 17-year-old age groups were similar, suggesting that route of infection does not play a 182 significant role in viral replication. When the positivity rates of individual age groups were compared to 183 adults, both the less than 1- and 17-year-old age groups demonstrated higher positive rates than adult 184 females. Increased surveillance for mpox in these age groups may be warranted in future outbreaks. 185 There are at least two documented cases of false positive mpox results from pediatric 186 specimens with late Ct values (14). To address this issue, the CDC recommended samples with a Ct of 34 187 or greater undergo repeat testing (21). Following this recommendation, our institution began 188 automatically repeating all positive samples from patients <18 years old. Prior to this, repeat testing was 189 performed based on clinical request or medical director discretion. The majority of specimens which did 190 not repeat (4 of 5) in our study were greater than 34 cycles. However, there was one specimen (Pt 17, 191 specimen 1) with an earlier Ct value of 33.3 which did not repeat. The second sample from this patient 192 was negative, and so the case was classified as inconclusive. If following the CDC guidelines, the first 193 specimen would not have been sent for repeat testing and may have led to a false positive result. 194 Failure of a late Ct to repeat should not be used as the sole factor to report a specimen as 195 positive or negative. True cases of mpox may also have samples that fail to repeat due to late Cts. For 196 example, Pt 23 had two specimens with late Cts (37.1 and 38.5) with the second specimen failing to 197 repeat. Given the similar presence of low MPXV in both specimens, we hypothesized these findings are 198 more reflective of an individual late in the disease course. Failure to re-amplify the 38.5 Ct specimen was 199 likely due to nucleic acid present below the limit of detection. Because Ct values of laboratory 200 developed tests can be influenced by a myriad of factors (primer/probe design, cycling conditions, curve 201 analysis), it is imperative that labs performing mpox testing have a robust understanding of their assay 202 and criteria for repeating. When a patient has discordant results or a late Ct result, it is reasonable for

203 the laboratory to repeat extraction and amplification of the specimens. Additionally, consultation with 204 the ordering provider may provide helpful context to the patient's exposure risks. However, even when 205 clinical information is available, epidemiological investigations may not provide a conclusive route of 206 mpox exposure (18). In a series of 83 cases of pediatric mpox in the US, 34% (28/83) were from 207 unknown routes of transmission (8). 208 Given the descriptive nature of our study and incomplete patient histories, our conclusions have several limitations. In our role as a reference laboratory, we lacked clinical information for the majority 209 210 of pediatric cases where mpox was detected. As a result, we retrospectively classified cases as "positive" 211 or "inconclusive" based on laboratory results and Bayesian reasoning. It is highly likely some of the 212 inconclusive cases are false positives and would further lower the positive predictive value of mpox 213 detection. Our guidelines for repeat testing of pediatric specimens changed over the course of the 214 study, and there were 4 samples with late Cts that were not repeated. 215 In summary, the pediatric age group comprises a minority of those tested for mpox and the 216 overall positivity rate is much lower than in adult males. Specimens from children are more frequently 217 from females and collected from non-genital sources. The age groups at highest risk of mpox appear to 218 be those less than 1 year of age and those 17 years of age. Inconclusive and false positive results 219 comprise a significant number of cases in which mpox is initially detected. Careful clinical correlation 220 and repeat testing of patient samples should be considered within this age group.

222 References

223	1.	McCollum AM, Damon IK. 2014. Human monkeypox. Clin Infect Dis 58:260–267.
224	2.	Parker S, Nuara A, Buller RML, Schultz DA. 2007. Human monkeypox: an emerging zoonotic
225		disease. Future Microbiol 2:17–34.
226	3.	Centers for Disease Control and Prevention (CDC). 2003. Update: multistate outbreak of
227		monkeypoxIllinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. MMWR Morb Mortal
228		Wkly Rep 52:642–646.
229	4.	Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, Palich R, Nori A, Reeves I,
230		Habibi MS, Apea V, Boesecke C, Vandekerckhove L, Yakubovsky M, Sendagorta E, Blanco JL,
231		Florence E, Moschese D, Maltez FM, Goorhuis A, Pourcher V, Migaud P, Noe S, Pintado C, Maggi F,
232		Hansen A-BE, Hoffmann C, Lezama JI, Mussini C, Cattelan A, Makofane K, Tan D, Nozza S, Nemeth J,
233		Klein MB, Orkin CM, SHARE-net Clinical Group. 2022. Monkeypox Virus Infection in Humans across
234		16 Countries - April-June 2022. N Engl J Med 387:679–691.
235	5.	WHO Director-General's statement at the press conference following IHR Emergency Committee
236		regarding the multi-country outbreak of monkeypox - 23 July 2022. https://www.who.int/director-
237		general/speeches/detail/who-director-general-s-statement-on-the-press-conference-following-
238		IHR-emergency-committee-regarding-the-multicountry-outbreak-of-monkeypox23-july-2022.
239		Retrieved 22 August 2022.
240	6.	Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, Steffen R. 2022. The changing
241		epidemiology of human monkeypox—A potential threat? A systematic review. PLOS Neglected
242		Tropical Diseases 16:e0010141.

243	7.	Philpott D, Hughes CM, Alroy KA, Kerins JL, Pavlick J, Asbel L, Crawley A, Newman AP, Spencer H,
244		Feldpausch A, Cogswell K, Davis KR, Chen J, Henderson T, Murphy K, Barnes M, Hopkins B, Fill M-
245		MA, Mangla AT, Perella D, Barnes A, Hughes S, Griffith J, Berns AL, Milroy L, Blake H, Sievers MM,
246		Marzan-Rodriguez M, Tori M, Black SR, Kopping E, Ruberto I, Maxted A, Sharma A, Tarter K, Jones
247		SA, White B, Chatelain R, Russo M, Gillani S, Bornstein E, White SL, Johnson SA, Ortega E, Saathoff-
248		Huber L, Syed A, Wills A, Anderson BJ, Oster AM, Christie A, McQuiston J, McCollum AM, Rao AK,
249		Negrón ME, CDC Multinational Monkeypox Response Team. 2022. Epidemiologic and Clinical
250		Characteristics of Monkeypox Cases - United States, May 17-July 22, 2022. MMWR Morb Mortal
251		Wkly Rep 71:1018–1022.
252	8.	Hennessee I, Shelus V, McArdle CE, Wolf M, Schatzman S, Carpenter A, Minhaj FS, Petras JK, Cash-
252	0.	
253		Goldwasser S, Maloney M, Sosa L, Jones SA, Mangla AT, Harold RE, Beverley J, Saunders KE, Adams
254		JN, Stanek DR, Feldpausch A, Pavlick J, Cahill M, O'Dell V, Kim M, Alarcón J, Finn LE, Goss M, Duwell
255		M, Crum DA, Williams TW, Hansen K, Heddy M, Mallory K, McDermott D, Cuadera MKQ, Adler E,
256		Lee EH, Shinall A, Thomas C, Ricketts EK, Koonce T, Rynk DB, Cogswell K, McLafferty M, Perella D,
257		Stockdale C, Dell B, Roskosky M, White SL, Davis KR, Milleron RS, Mackey S, Barringer LA, Bruce H,
258		Barrett D, D'Angeli M, Kocharian A, Klos R, Dawson P, Ellington SR, Mayer O, Godfred-Cato S,
259		Labuda SM, McCormick DW, McCollum AM, Rao AK, Salzer JS, Kimball A, Gold JAW, California
260		Department of Public Health Monkeypox Pediatric Working Group, CDC Monkeypox Pediatric
261		Working Group, California Department of Public Health Monkeypox Pediatric Working Group,
262		Berumen R, Cosentino G, Getabecha S, Glaser C, Grosgebauer K, Harriman K, Haw M, Kamali A,
263		Kath C, Kim EH, Lewis LS, Sachdev D, Salas M, Stainken C, Wadford DA, Peters PJ, Vaidya A, CDC
264		Monkeypox Pediatric Working Group, Hocevar Adkins S, Baird ; Nicolle, Barrios LC, Beeson A,
265		Blackburn D, Borah BF, Click E, Davidson W, Galang RR, Hufstetler K, Hutchins HJ, Kourtis AP, Miller
266		MJ, Bamrah Morris S, Olsen EO, Roth NM, Sims E, Chatham-Stephens K. 2022. Epidemiologic and

- 267 Clinical Features of Children and Adolescents Aged <18 Years with Monkeypox United States,
- 268 May 17–September 24, 2022. MMWR Morb Mortal Wkly Rep 71:1407–1411.
- 269 9. Ježek Z, Grab B, Szczeniowski M, Paluku KM, Mutombo M. 1988. Clinico-epidemiological features
- 270 of monkeypox patients with an animal or human source of infection. Bull World Health Organ
- 66:459–464.
- 272 10. Beeson AM, Haston J, McCormick DW, Reynolds M, Chatham-Stephens K, McCollum AM, Godfred-
- 273 Cato S. 2022. Mpox in Children and Adolescents: Epidemiology, Clinical Features, Diagnosis, and
- 274 Management. Pediatrics https://doi.org/10.1542/peds.2022-060179.
- 275 11. Aguilera-Alonso D, Alonso-Cadenas JA, Roguera-Sopena M, Lorusso N, Miguel LGS, Calvo C. 2022.
- 276 Monkeypox virus infections in children in Spain during the first months of the 2022 outbreak. The
- 277 Lancet Child & Adolescent Health 6:e22–e23.
- 12. Skittrall JP, Wilson M, Smielewska AA, Parmar S, Fortune MD, Sparkes D, Curran MD, Zhang H, Jalal
- 279 H. 2021. Specificity and positive predictive value of SARS-CoV-2 nucleic acid amplification testing in
- a low-prevalence setting. Clin Microbiol Infect 27:469.e9-469.e15.
- 281 13. Zimmermann P, Curtis N. 2022. Monkeypox—What Pediatricians Need to Know. The Pediatric
 282 Infectious Disease Journal 41:1020.
- Minhaj FS. 2022. Orthopoxvirus Testing Challenges for Persons in Populations at Low Risk or
 Without Known Epidemiologic Link to Monkeypox United States, 2022. MMWR Morb Mortal
 Wkly Rep 71.

- 15. Lieberman NAP, Mathias PC, Bradley BT, Greninger AL. 2022. Clinical Performance and Trends
- 287 during the First Two Months of Monkeypox Virus PCR Testing at Two United States Reference Labs.
- 288 Journal of Clinical Microbiology 0:e01371-22.
- 289 16. Li Y, Olson VA, Laue T, Laker MT, Damon IK. 2006. Detection of monkeypox virus with real-time
- 290 PCR assays. J Clin Virol 36:194–203.
- 17. Ramnarayan P, Mitting R, Whittaker E, Marcolin M, O'Regan C, Sinha R, Bennett A, Moustafa M,
- 292 Tickner N, Gilchrist M, Kershaw A, Rampling T. 2022. Neonatal Monkeypox Virus Infection. New
- 293 England Journal of Medicine 387:1618–1620.
- 18. Furth AMT van, Kuip M van der, Els AL van, Fievez LC, Rijckevorsel GG van, Ouden A van den,
- Jonges M, Welkers MR. 2022. Paediatric monkeypox patient with unknown source of infection, the
 Netherlands, June 2022. Eurosurveillance 27:2200552.
- 297 19. Saunders KE. 2022. Monkeypox in a Young Infant Florida, 2022. MMWR Morb Mortal Wkly Rep
 298 71.
- 20. Becker TM, Magder L, Harrison HR, Stewart JA, Humphrey DD, Hauler J, Nahmias AJ. 1988. The
 epidemiology of infection with the human herpesviruses in Navajo children. Am J Epidemiol
 127:1071–1078.
- 2022. Lab Advisory: Monkeypox Virus Testing Considerations to Prevent False Positive Test
 Results. https://www.cdc.gov/locs/2022/08-23-2022-Lab-Advisory-
- 304 Monkeypox_Virus_Testing_Considerations_Prevent_False_Positive_Test_Results.html. Retrieved
 305 16 January 2023.
- 306
- 307